INHIBITION OF DEBRISOQUINE METABOLISM BY PROPAFENONE IN MAN

被引：0
|
作者：
SIDDOWAY, LA
MCALLISTER, CB
THOMPSON, KA
BARBEY, JT
WILKINSON, GR
RODEN, DM
WOOSLEY, RL
机构：
[1] VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37240
[2] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37240
来源：
CLINICAL RESEARCH | 1985年 / 33卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：A288 / A288
页数：1
相关论文
共 50 条
  • [41] METABOLISM OF DEBRISOQUINE AND SUSCEPTIBILITY TO BREAST-CANCER
    HUOBER, J
    BERTRAM, B
    PETRU, E
    KAUFMANN, M
    SCHMAHL, D
    BREAST CANCER RESEARCH AND TREATMENT, 1991, 18 (01) : 43 - 48
  • [42] INHIBITION BY ISONIAZID OF VITAMIN-D METABOLISM IN MAN
    BRODIE, MJ
    BOOBIS, AR
    HILLYARD, CJ
    ABEYASEKERA, G
    MACINTYRE, I
    PARK, BK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 11 (04) : P422 - P422
  • [43] NONLINEAR KINETICS OF PROPAFENONE METABOLITES IN HEALTHY MAN
    VOZEH, S
    HAEFELI, W
    HA, HR
    VLCEK, J
    FOLLATH, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (05) : 509 - 513
  • [44] SIMULTANEOUS PHENOTYPING FOR CAFFEINE ACETYLATION AND DEBRISOQUINE HYDROXYLATION IN MAN
    RICHARD, MO
    BIEDERROSEMBERG, V
    CARRIER, O
    REY, E
    PONS, G
    OLIVE, G
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1987, 1 (05) : 371 - 371
  • [45] NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO DEBRISOQUINE HYDROXYLATION IN MAN
    BERTILSSON, L
    EICHELBAUM, M
    MELLSTROM, B
    SAWE, J
    SCHULZ, HU
    SJOQVIST, F
    LIFE SCIENCES, 1980, 27 (18) : 1673 - 1677
  • [46] INFLUENCE OF DEBRISOQUINE PHENOTYPE AND OF QUINIDINE ON MEXILETINE DISPOSITION IN MAN
    TURGEON, J
    FISET, C
    GIGUERE, R
    GILBERT, M
    MOERIKE, K
    ROULEAU, JR
    KROEMER, HK
    EICHELBAUM, M
    GRECHBELANGER, O
    BELANGER, PM
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 259 (02): : 789 - 798
  • [47] THE METABOLISM OF DEBRISOQUINE IN MAN - (1) REGIOSELECTIVITY OF HYDROXYLATION AND (2) ABERRANT OXIDATIVE-METABOLISM IN 2 SIBLING PATIENTS WITH CARBIMAZOLE-INDUCED AGRANULOCYTOSIS
    RITCHIE, JC
    CROTHERS, MJ
    SHAH, RR
    IDLE, JR
    SMITH, RL
    XENOBIOTICA, 1986, 16 (05) : 503 - 509
  • [48] DETERMINATION OF DEBRISOQUINE SPARTEINE PHENOTYPE DURING CHRONIC PROPAFENONE THERAPY - A NEW APPROACH USING INTACT CONJUGATES
    KROEMER, HK
    TURGEON, J
    PRAKASH, C
    FUNCKBRENTANO, C
    RODEN, DM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (03) : 1074 - 1074
  • [49] PHENOTYPIC EFFECTS ON THE ABILITY TO INDUCE DEBRISOQUINE (D) METABOLISM
    ZHOU, HH
    WILKINSON, GR
    WOOD, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 174 - 174
  • [50] Is there any difference between daytime and nighttime debrisoquine metabolism?
    Bordet, R
    Belabbas, A
    Lhermitte, M
    Tricot, O
    Roussel, P
    Libersa, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 419 - 420
12345